Objective:

To discuss whether addressing both trabecular and uveoscleral outflow pathways in surgical settings could improve outcomes for moderate to advanced glaucoma patients.

Approach:

Key Findings:

• Uveoscleral outflow agents are more efficacious than trabecular outflow agents.
• Current surgical practices predominantly focus on trabecular outflow.
• Innovations like AlloFlo and AlloSpan aim to enhance both outflow pathways.
• A combined approach may reshape treatment paradigms for glaucoma surgery.

Interpretation:

A combined approach targeting both outflow pathways may provide a more innovative and comprehensive solution for moderate to advanced glaucoma patients.

Limitations:

• Limited data on the long-term outcomes of targeting both pathways.
• Need for further studies, including randomized controlled trials, to establish the efficacy of combined interventions.

Conclusion:

Exploring total outflow interventions could reshape treatment paradigms for glaucoma surgery, emphasizing the need for comprehensive solutions.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.